Search Results

First Validation of Novel PRI Technology: Existing PET Tracers Can Image Tissue Microenvironment

August 6, 2026 - A joint research team from the Graduate School of Engineering at the University of Tokyo and the University of York in the UK announced that they have established a novel geometric imaging principle utilizing positron three-photon decay and successfully validated Positronium Ratio Imaging (PRI) technology for the first time. This method can be used in conjunction with existing clinical PET tracers and is expected to provide a new means of observing tissue microenvironments in nuclear medicine imaging. Conceptual diagram of next-generation nuclear medicine imaging utilizing positron-3-photon decay. Current clinical PET scans primarily rely on the positron two-photon annihilation process to visualize the distribution and accumulation of tracers in the body, but they provide limited information on microenvironmental factors such as tissue hypoxia that are associated with disease malignancy...

2026-08-07

Construction of Proton Therapy Center in Ulsan, South Korea Faces Hurdles: Government Funding Allocation Adjustments Impact Project Progress

The proton therapy center construction project in Ulsan, South Korea, has recently encountered obstacles to progress. The project was once regarded as a key component in improving the regional cancer treatment system in southeastern South Korea, but due to shifts in government medical financial support priorities, the difficulty of securing large-scale national funding independently has increased significantly. According to information from Ulsan City on August 6, Ulsan City completed the feasibility study and basic planning services for the proton therapy center construction in March of last year and began seeking national funding. However, the Ministry of Health and Welfare responded that it would be difficult to provide large-scale project funding to Ulsan City alone. Previously, Ulsan City had planned to establish a proton therapy center to build a system enabling cancer patients to undergo surgery...

2026-08-07

Japanese PET Study Suggests Late-Onset Psychosis May Be Linked to Neurodegenerative Pathology

A nuclear medicine imaging study conducted by a Japanese research team has shown that many adults who experience psychotic symptoms such as hallucinations and delusions for the first time after age 40 have abnormal protein deposits in the brain associated with Alzheimer's disease and other neurodegenerative disorders. The study included 37 patients with late-onset psychosis and 47 age-matched healthy controls. The researchers used the amyloid PET tracer ^11C-PiB and the tau protein PET tracer ^18F-florzolotau to assess the accumulation of β-amyloid and tau proteins in the participants' brains. The results showed that among patients with late-onset psychosis, β-amyloid positivity...

2026-08-06

Thor Medical Commences Commercial Supply with First Delivery of High-Purity Thorium-228 from AlphaOne

Thor Medical ASA announced on August 5 that it has completed the first customer delivery of high-purity thorium-228 (Th-228) from its AlphaOne production facility at the Herøya industrial park. This marks the first customer shipment following the facility's production start announced last week, and signifies AlphaOne's entry into the commercial supply phase. Thor Medical CEO Jasper Kurth stated that commercial production represents the beginning of the company's industrial-scale manufacturing, and the first customer delivery demonstrates the company's transition from capacity building to serving customers through its first industrial-scale facility. The company stated that as production capacity gradually ramps up, it will continue to meet the growing demand for high-purity isotopes in the targeted alpha therapy field...

2026-08-06

Quantum X Labs Advances Quantum Computing for Nuclear Particle Transport Predictive Simulations

Quantum X Labs Inc. recently announced that its subsidiary, Nuclear Quantum, has proposed a new solution to a bottleneck in computational simulations for the nuclear industry, attempting to introduce quantum computing into nuclear particle transport prediction to support compute-intensive scenarios such as nuclear medicine system design. According to reports, traditional particle transport simulations play an important role in nuclear medicine system design, but they often require substantial computational resources and involve long runtimes, impacting R&D and optimization efficiency. The technology proposed by Nuclear Quantum aims to transform physical transport models into quantum circuits, enabling particle propagation and random walk dynamics to be directly represented and simulated within a quantum computing framework...

2026-08-06

South Korea advances plan to produce medical isotopes using nuclear power plants, with lutetium-177 targeted for commercial production in 2031

South Korea is advancing plans to industrialize the production of radioisotopes using nuclear power plants, with the medical isotope lutetium-177 (Lu-177) designated as the first commercial target product. Korea Hydro & Nuclear Power stated that it plans to prioritize the commercialization of Lu-177 production, with the potential to later expand the product range to include isotopes such as cobalt-60, tritium-3, and helium-3. Lu-177 is a therapeutic radioisotope widely used in the global radiopharmaceutical market, applicable in radiopharmaceuticals for diseases such as prostate cancer and neuroendocrine tumors. Previously, South Korea relied entirely on imports for its Lu-177 supply. Due to its half-life of approximately 6.6 days, the entire process from production and transportation to drug preparation and patient administration...

2026-08-06

Han Bing, Chairman of Hefei Municipal CPPCC, Leads Delegation to CYC Ion for Research and Guidance

On the afternoon of August 4, Han Bing, Chairman of Hefei Municipal Committee of the Chinese People's Political Consultative Conference (CPPCC), led a delegation to CYC Ion for research and guidance, and held a symposium. Yong Fengshan, Deputy Director of the Standing Committee of the Municipal People's Congress; Su Xiang, Secretary-General of the Municipal CPPCC; Jiang Xin, Chairman of the Municipal Industrial Investment Group; Zhang Xiaofeng, Director of the Education, Science, Health and Sports Committee of the Municipal CPPCC; and Guo Mei, Deputy Director of the Municipal Bureau of Industry and Information Technology, participated in the event. Song Yuntao, Deputy Director of the Hefei Institutes of Physical Science, Chinese Academy of Sciences; Liu Lu, Chairman of CYC Ion; Chen Yonghua, General Manager; and Deputy General Managers Ding Kaizhong, Li Jun, and Guang Ruohuai accompanied the delegation. The delegation was briefed in detail on CYC Ion's industrial layout and business operations, with discussions focusing on key technological breakthroughs in nuclear medicine and high-end equipment, technology transfer and commercialization, and industrial development.

2026-08-06

CNNC & CIR Co-sponsors Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project Launched Simultaneously

Recently, the Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and the Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project were launched simultaneously at Ganzhou Cancer Hospital. An expert panel from the Nuclear Medicine Branch of the Chinese Medical Association, along with representatives from CNNC & CIR and Atom High-Tech, visited the hospital for research and exchange. More than 200 medical staff from medical institutions at various levels across Jiangxi Province attended the event. The launch ceremony was moderated by Yang Chuansheng, Director of the Nuclear Medicine Department at Ganzhou Cancer Hospital. Fu Wei, Deputy Director of the Ganzhou Municipal Health Commission; Wang Jing, Chair of the Nuclear Medicine Branch of the Chinese Medical Association; and Huang Xingwei, Party Secretary of Ganzhou Cancer Hospital, attended and delivered speeches. Wang Jing stated that nuclear medicine plays a vital supporting role in the precise diagnosis and treatment of major diseases such as cancer, and that promoting the standardized development of regional nuclear medicine at the city and county levels is conducive to channeling high-quality medical resources to the grassroots and enhancing primary healthcare service capabilities.

2026-08-06

Zhang Yiming, Chairman of HTA: Tackling the "Last Mile" of Nuclear Pharmacy Network Delivery to Bring Domestic Radiopharmaceuticals to Patients in Western and County-Level Regions

On July 28, the 2026 Radiopharmaceutical Innovation and Development Conference was held in Taiyuan, Shanxi Province. Zhang Yiming, Party Committee Secretary and Chairman of HTA, told reporters that the company is restructuring its short half-life radiopharmaceutical delivery system through "regional layout + standardized logistics + grassroots empowerment," striving to ensure that cancer patients in western and county-level regions can access domestically produced radiopharmaceuticals within the drug's effective half-life window. Currently, multi-dimensional policy dividends are being continuously released, and China's radiopharmaceutical industry is entering a critical window of opportunity. Alpha nuclide drugs represent the future direction of therapeutic radiopharmaceuticals. Zhang Yiming introduced that HTA has already made early arrangements for drug research in this field, jointly conducting research on actinium-225 labeled...

2026-08-05

Samsung and Accuray Plan Collaboration on Image-Guided Precision Radiation Therapy

Samsung Electronics' medical device business and Samsung Medison continue to shift their business focus from medical diagnostics to treatment. On August 5, Samsung HME America and U.S. radiosurgery company Accuray announced the signing of a non-binding letter of intent to explore collaboration on volume imaging-based precision radiation therapy solutions. Under the letter of intent, the two parties plan to study the integration of Samsung's mobile CT scanner BodyTom with Accuray's robotic radiosurgery platform CyberKnife. This collaboration direction aims to connect high-resolution 3D imaging capabilities with image-guided robotic radiosurgery technology, enabling medical staff to more accurately identify...

2026-08-05

US Intermountain Health Opens New Outpatient Clinic in Las Vegas, Equipped with PET/CT and Linear Accelerator

Intermountain Health, headquartered in Salt Lake City, recently opened a new outpatient clinic in southwest Las Vegas. Named Badura Clinic, the facility spans approximately 90,000 square feet and is located in the Spring Valley area, marking the health system's first new construction project in Nevada. The three-story Badura Clinic officially opened following a ribbon-cutting ceremony and community open house on July 30. The clinic consolidates primary care and select specialty services previously dispersed across multiple locations in the Las Vegas Valley, offering more centralized medical care for children, adults, and senior patients. According to the introduction, the clinic's services include adult and...

2026-08-05

ASP Isotopes PET Lab Revenue Grows Over 50% in First Half of Year, Isotope Enrichment Facilities Advance Toward Commercial Production

ASP Isotopes Inc. recently released a letter to shareholders outlining operational progress across its business segments ahead of the company's second-quarter 2026 financial results announcement. The company stated that its PET lab segment achieved organic revenue growth of more than 50% in the first half of 2026 compared to the same period in 2025. Based on current expectations, the segment's full-year 2026 revenue is projected to be approximately $14 million, up from $6 million in 2025. PET-related operations are typically closely associated with radiopharmaceutical preparation, molecular imaging, and nuclear medicine diagnostic applications. On the isotope front, ASP Isotopes stated that its silicon-28 and ytterbium-176 enrichment facilities have entered the final stage before commercial production, with first deliveries expected in the second half of 2026...

2026-08-05

BWXT to Sell Medical Business to Nordic Capital for Up to $800 Million

On August 3, BWX Technologies, Inc. announced that it has reached a definitive agreement to sell its medical business to healthcare investment company Nordic Capital. The transaction is valued at up to $800 million and includes BWXT Medical and the stable medical isotope business of Kinectrics. BWXT stated that the divestiture will help the company concentrate resources and capital to drive growth in its core nuclear national security business and commercial nuclear power market operations. The company believes these areas are its long-term strategic priorities. Under Nordic Capital's ownership, the medical business is expected to further expand its scale, enhance capabilities, and strengthen its position in the radiopharmaceutical field...

2026-08-04

Curium and Lantheus Reach Definitive Merger Agreement to Build a Global Integrated Radiopharmaceutical Theranostics Platform

On August 3, global radiopharmaceutical company Curium announced that it has entered into a definitive merger agreement with Lantheus Holdings, Inc. Under the agreement, Curium US Holdings LLC will merge with Lantheus through its wholly owned subsidiary, with a total consideration of up to $114.50 per share and a total transaction value of approximately $8 billion. Under the terms of the agreement, Curium US will acquire all outstanding shares of Lantheus at $102.50 per share in cash upon closing of the transaction. In addition, Lantheus shareholders will receive non-transferable contingent value rights, entitling them to up to $12.00 per share in additional cash payments if certain commercial milestones for Lantheus-related products are achieved by 2030...

2026-08-04

UT-ORNL Recruits Radiopharmaceutical Scientist to Advance Integrated Cancer Diagnosis and Treatment

The University of Tennessee and Oak Ridge National Laboratory jointly announced that Dr. Carolyn Anderson has been appointed to the UT-ORNL Governor's Chair in Nuclear Medicine: Radiopharmaceutical Therapy. Anderson officially assumed the position on August 1, serving concurrently as a professor in the Department of Nuclear Engineering at the University of Tennessee, Knoxville, and as a researcher in the Isotope Science and Enrichment Directorate at Oak Ridge National Laboratory. She is an internationally renowned pioneer in the field of radiopharmaceutical science, having worked at institutions such as the University of Washington, the University of Pittsburgh, and the University of Missouri. Dr. Anderson's research focuses on developing compounds that can identify cancer earlier, assess treatment efficacy, and deliver radiation directly to tumors...

2026-08-04